Tempest Therapeutics, Inc. — Director's Dealing 2018

Mar 6, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2018-03-06

Reporting Person: Lillie James Woodruff (Chief Scientific Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-03-06	Stock Option (right to buy)	$1.02	A	357057	Acquired	2028-03-05	Common Stock (357057)	Direct

Footnotes

F1: The shares underlying this option shall vest as to 25% of the shares on the first anniversary of the commencement of the Reporting Person's employment (which began on January 16, 2018), with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.